Literature DB >> 26556564

Analysis and validation of traits associated with a single nucleotide polymorphism Gly364Ser in catestatin using humanized chromogranin A mouse models.

Saiful A Mir1, Kuixing Zhang, Milos Milic, Yusu Gu, Timo Rieg, Michael Ziegler, Sucheta M Vaingankar.   

Abstract

OBJECTIVE: The human prohormone chromogranin A (CHGA), an index member of the granin family is processed to generate catestatin, a peptide that is hypotensive in action and modulates catecholamine release within the sympathoadrenal system. Hypertensive patients with excess sympathetic activity have diminished catestatin. Often the study of physiological consequences of human genetic variation is confounded by elements such as other variations in obligatory linkage disequilibrium with the variant being studied. Also the phenotype of the variant may be influenced by genetic background that varies amongst individuals. This study addresses the effects of a human catestatin polymorphism (rs9658667) using humanized CHGA mouse models.
METHODS: We created pertinent humanized mouse models wherein the mouse Chga gene locus was replaced by the human ortholog wild-type and the variant versions. This allowed for probing of the effects of catestatin variation in vivo with controls for other variations and global genetic background.
RESULTS: Both the wild-type and variant human catestatin expressing mouse models were normotensive. The variant catestatin mouse model recapitulated physiological influence of the polymorphism on autonomic traits. These mice had diminished catecholamine, attenuated stress response and increased baroreceptor slopes that would suggest reduced risk of developing hypertension. Elevated plasma glucose, a trait observed in humans was not observed in mice expressing the variant catestatin.
CONCLUSION: This functional genomics approach of creating humanized mouse models to study rs9658667 polymorphism recapitulated and validated many of the human trait associations. This approach can also be applied in the study of other human gene polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26556564      PMCID: PMC5580682          DOI: 10.1097/HJH.0000000000000760

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  43 in total

1.  Catestatin (chromogranin A(352-372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling.

Authors:  Gautam K Bandyopadhyay; Christine U Vu; Stefano Gentile; Howon Lee; Nilima Biswas; Nai-Wen Chi; Daniel T O'Connor; Sushil K Mahata
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

Review 2.  Cardio-vascular activity of catestatin: interlocking the puzzle pieces.

Authors:  R Mazza; B Tota; A Gattuso
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

3.  Suppression of chromogranin-A release from neuroendocrine sources in man: pharmacological studies.

Authors:  M A Takiyyuddin; A D Baron; J H Cervenka; J A Barbosa; H P Neumann; R J Parmer; P A Sullivan; D T O'Connor
Journal:  J Clin Endocrinol Metab       Date:  1991-03       Impact factor: 5.958

4.  Applicability of recent methods used to estimate spontaneous baroreflex sensitivity to resting mice.

Authors:  Dominique Laude; Véronique Baudrie; Jean-Luc Elghozi
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-11-07       Impact factor: 3.619

5.  Chromogranin A polymorphisms are associated with hypertensive renal disease.

Authors:  Rany M Salem; Peter E Cadman; Yuqing Chen; Fangwen Rao; Gen Wen; Bruce A Hamilton; Brinda K Rana; Douglas W Smith; Mats Stridsberg; Harry J Ward; Manjula Mahata; Sushi K Mahata; Donald W Bowden; Pamela J Hicks; Barry I Freedman; Nicholas J Schork; Daniel T O'Connor
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

6.  Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure.

Authors:  Y Chen; F Rao; J L Rodriguez-Flores; N R Mahapatra; M Mahata; G Wen; R M Salem; P-A B Shih; M Das; N J Schork; M G Ziegler; B A Hamilton; S K Mahata; D T O'Connor
Journal:  Kidney Int       Date:  2008-04-23       Impact factor: 10.612

Review 7.  Pancreastatin is an endogenous peptide that regulates glucose homeostasis.

Authors:  Guru Raghavendra Valicherla; Zakir Hossain; Sushil K Mahata; Jiaur R Gayen
Journal:  Physiol Genomics       Date:  2013-09-24       Impact factor: 3.107

8.  Naturally occurring human genetic variation in the 3'-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion.

Authors:  Yuqing Chen; Fangwen Rao; Juan L Rodriguez-Flores; Manjula Mahata; Maple M Fung; Mats Stridsberg; Sucheta M Vaingankar; Gen Wen; Rany M Salem; Madhusudan Das; Myles G Cockburn; Nicholas J Schork; Michael G Ziegler; Bruce A Hamilton; Sushil K Mahata; Laurent Taupenot; Daniel T O'Connor
Journal:  J Am Coll Cardiol       Date:  2008-10-28       Impact factor: 24.094

9.  The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol.

Authors:  Murtaza Emre Durakoğlugil; Teslime Ayaz; Sinan Altan Kocaman; Aynur Kırbaş; Tuğba Durakoğlugil; Turan Erdoğan; Mustafa Çetin; Osman Zikrullah Şahin; Yüksel Çiçek
Journal:  Anatol J Cardiol       Date:  2014-07-17       Impact factor: 1.596

10.  MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension.

Authors:  Ryan S Friese; Angelina E Altshuler; Kuixing Zhang; Jose Pablo Miramontes-Gonzalez; C Makena Hightower; Martin L Jirout; Rany M Salem; Jiaur R Gayen; Nitish R Mahapatra; Nilima Biswas; Mo Cale; Sucheta M Vaingankar; Hyung-Suk Kim; Maïté Courel; Laurent Taupenot; Michael G Ziegler; Nicholas J Schork; Michal Pravenec; Sushil K Mahata; Geert W Schmid-Schönbein; Daniel T O'Connor
Journal:  Hum Mol Genet       Date:  2013-05-13       Impact factor: 6.150

View more
  5 in total

Review 1.  Genetic-Driven Druggable Target Identification and Validation.

Authors:  Matteo Floris; Stefania Olla; David Schlessinger; Francesco Cucca
Journal:  Trends Genet       Date:  2018-05-23       Impact factor: 11.639

Review 2.  Animal Models of Hypertension: A Scientific Statement From the American Heart Association.

Authors:  Lilach O Lerman; Theodore W Kurtz; Rhian M Touyz; David H Ellison; Alejandro R Chade; Steven D Crowley; David L Mattson; John J Mullins; Jeffrey Osborn; Alfonso Eirin; Jane F Reckelhoff; Costantino Iadecola; Thomas M Coffman
Journal:  Hypertension       Date:  2019-06       Impact factor: 10.190

3.  Mice overexpressing chromogranin A display hypergranulogenic adrenal glands with attenuated ATP levels contributing to the hypertensive phenotype.

Authors:  Saiful A Mir; Ying Li; Jacob D Story; Soma Bal; Linda Awdishu; Anneke A Street; Ravindra L Mehta; Prabhleen Singh; Sucheta M Vaingankar
Journal:  J Hypertens       Date:  2018-05       Impact factor: 4.844

Review 4.  Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.

Authors:  Angelo Corti; Fabrizio Marcucci; Tiziana Bachetti
Journal:  Pflugers Arch       Date:  2017-10-10       Impact factor: 3.657

5.  Chromogranin A pathway: from pathogenic molecule to renal disease.

Authors:  Saiful A Mir; Nilima Biswas; Wai Cheung; Ji Wan; Nicholas Webster; Etienne Macedo; Daniel T O'Connor; Sucheta M Vaingankar
Journal:  J Hypertens       Date:  2020-03       Impact factor: 4.776

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.